Results 61 to 70 of about 12,338 (219)
Neurotoxicity of stem cell mobilization chemotherapy with vinorelbine in myeloma patients after bortezomib treatment. [PDF]
, 2015 Vinorelbine chemotherapy with G-CSF stimulation is the standard mobilization regimen in Switzerland for multiple myeloma patients. However, with the increasing use of bortezomib during induction treatment, adding the neurotoxic compound vinorelbine for ...
Pabst, Thomas +6 more
core +1 more source
Frontiers in Cell and Developmental BiologyStudies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by the abnormalities of various molecules and microenvironments. Exploring these resistance mechanisms will improve the therapeutic efficacy of bortezomib.
Siyi Jiang +5 more
doaj +1 more source
Molecular Pain, 2019 The incidence of bortezomib-induced neuropathic pain hampers the progress of therapy for neoplasia and also negatively affects the quality of life of patients.
Yaochao Zheng +7 more
doaj +1 more source
Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
Parasites & Vectors, 2009 The proteasome inhibitor and anti-cancer drug bortezomib was tested for in vitro activity against bloodstream forms of Trypanosoma brucei. The concentrations of bortezomib required to reduce the growth rate by 50% and to kill all trypanosomes were 3.3 nM
Wang Xia, Steverding Dietmar
doaj +1 more source
Discovery of CRBN‐based molecular glue degraders targeting WIZ transcription factor
Bulletin of the Korean Chemical Society, EarlyView.This work reports the discovery of 9l, a novel cereblon‐based molecular glue degrader which targets the WIZ transcription factor. Compound 9l facilitates WIZ‐CRBN ternary complex formation to degrade WIZ, subsequently inducing γ‐globin expression in HUDEP‐2 cells and highlighting its potential as a sickle cell disease therapy.
Tae‐Jun Kim +8 more
wiley +1 more source
Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy
BMEMat, EarlyView.This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang +5 more
wiley +1 more source
Haematologica, 2012 The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma.
Bertrand Arnulf +9 more
doaj +1 more source
iLABMED, EarlyView.This article reviews the pivotal role of post‐translational modifications of proteins in the development and progression of hematologic malignancies, and explores their clinical translation potential as novel biomarkers and therapeutic targets. ABSTRACT Post‐translational modifications (PTMs) of proteins have emerged as critical regulators in the ...
Yuxuan Han +6 more
wiley +1 more source
, 2008 We investigated the cytotoxicity and biology of the novel broad-spectrum hydroxamic acid-based histone deacetylase inhibitor (HDACi), PCI-24781. PCI-24781 was studied alone and combined with bortezomib in Hodgkin lymphoma (L428) and non-Hodgkin's ...
Kevin David +9 more
core